Metraipolis › archive › dc_44982acfdade

An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor — Europe PMC PMID:40908570

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40908570
DOI: 10.1002/cam4.71191
License (as archived): solo-consultazione
Archived: 2026-11-10T05:56:37.365Z
SHA-256 of the archived text: bff4f285102921c553792425ac1403a5ffba81894dab80c75fe8d7269785b4dc
Stable URL of this page: https://metraipolis.com/documento/dc_44982acfdade

How to cite

An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor — Europe PMC PMID:40908570 — Europe PMC (en), https://europepmc.org/article/MED/40908570 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_44982acfdade (Metraipolis archive dc_44982acfdade, sha256 bff4f285102921c553792425ac1403a5ffba81894dab80c75fe8d7269785b4dc)

BibTeX

@misc{dc44982acfdade,
  title = {An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor — Europe PMC PMID:40908570},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40908570},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_44982acfdade; sha256 bff4f285102921c553792425ac1403a5ffba81894dab80c75fe8d7269785b4dc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40908570. Agents can read the archived copy with the MCP tool read_document.